ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression

Pharmacogenomics

Volumn 14, Issue 12, 2013, Pages 1433-1448

  Magdy, Tarek ^a   Arlanov, Rudolf ^a   Winter, Stefan ^a   Lang, Thomas ^a   Klein, Kathrin ^a   Toyoda, Yu ^b   Ishikawa, Toshihisa ^c   Schwab, Matthias ^a,d   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

5 fluorouracil; ABCC11; drug transporter; drug metabolizing enzyme; haplotype; leukopenia; pharmacogenetics; pharmacogenomics; polymorphism; toxicity

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; LEVAMISOLE; MESSENGER RNA; PROTEIN MRP8; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CAUCASIAN; CHROMOSOME 16; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; EMBRYO; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MARKER GENE; MONOTHERAPY; MRP8 GENE; MUCOSA INFLAMMATION; PROTEIN EXPRESSION; QUANTITATIVE TRAIT LOCUS; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOPENIA; LIVER; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84883895294     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.139     Document Type: Article

References (66)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003
2. Fata F, Mirza A, Craig G et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: A 10 year experience of the Geisinger Medical Center. Cancer 94(7), 1931-1938 (2002
3. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131-2138 (2008
4. Eliason JF, Megyeri A. Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr. Drug Targets 5(4), 383-388 (2004
5. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: Fluoropyrimidine pathways. Pharmacogenet. Genomics 21(4), 237-242 (2011
6. Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: Implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics 8(3), 257-265 (2007
7. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 48(2), 189-222 (1990
8. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9), 1321-1336 (2011
9. Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J. Int. Med. Res. 38(3), 870-883 (2010
10. Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3(12), e4003 (2008
11. Zhu AX, Puchalski TA, Stanton VP et al. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/ leucovorin chemotherapy in colorectal cancer. Clin. Colorectal Cancer 3(4), 225-234 (2004
12. Afzal S, Jensen SA, Vainer B et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol. 20(10), 1660-1666 (2009
13. Capitain O, Boisdron-Celle M, Poirier AL, Abadie-Lacourtoisie S, Morel A, Gamelin E. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J. 8(4), 256-267 (2008
14. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug Monit. 29(2), 190-196 (2007
15. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol. 69(1), 58-66 (2010
16. Gusella M, Frigo AC, Bolzonella C et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br. J. Cancer 100(10), 1549-1557 (2009
17. Lecomte T, Ferraz JM, Zinzindohoué F et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 10(17), 5880-5888 (2004
18. Marcuello E, Altés A, del Rio E, César A, Menoyo A, Baiget M. Single nucleotide polymorphism in the 5́ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int. J. Cancer 112(5), 733-737 (2004
19. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006
20. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73(6), 1958-1968 (2013
21. Akiyama Y, Fujita KI, Ishida H et al. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab. Pharmacokinet. 27(3), 325-335 (2012
22. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-2005. J. Clin. Oncol. 28(15), 2556-2564 (2010
23. Fidlerova J, Kleiblova P, Kormunda S, Novotny J, Kleibl Z. Contribution of the b-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity. Pharmacol. Rep. 64(5), 1234-1242 (2012
24. Fidlerova J, Kleiblova P, Bilek M et al. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother. Pharmacol. 65(4), 661-669 (2010
25. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin. Cancer Res. 12(13), 3928-3934 (2006
26. Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity nd response in patients with advanced colorectal cancer. Pharmacogenomics J. 11(1), 61-71 (2011
27. Fernandez-Rozadilla C, Cazier JB, Moreno V et al. Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 13(3), 209-217 (2012
28. Janke D, Mehralivand S, Strand D et al. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat. 29(5), 659-669 (2008
29. Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59(11), 2532-2535 (1999
30. Bessho Y, Oguri T, Ozasa H et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol. Rep. 21(1), 263-268 (2009
31. Uemura T, Oguri T, Ozasa H et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 101(11), 2404-2410 (2010
32. Tammur J, Prades C, Arnould I et al. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene 273(1), 89-96 (2001
33. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-b-d-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. 67(2), 545-557 (2005
34. Guo Y, Kotova E, Chen ZS et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2́,3́-dideoxycytidine and 9́-(2́- phosphonylmethoxyethyl)adenine. J. Biol. Chem. 278(32), 29509-29514 (2003
35. Oguri T, Bessho Y, Achiwa H et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 6(1), 122-127 (2007
36. Yoshiura K, Kinoshita A, Ishida T et al. A SNP in the ABCC11 gene is the determinant of human earwax type. Nat. Genet. 38(3), 324-330 (2006
37. Schröder A, Klein K, Winter S et al. Genomics of ADME gene expression: Mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics J. 13(1), 12-20 (2011
38. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front. Pharmacol. 1, 129 (2010
39. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005
40. de Bakker PIW, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 37(11), 1217-1223 (2005
41. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 37(Web Server Issue), W600-W605 (2009
42. Sherry ST, Ward MH, Kholodov M et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001
43. Gomes AM, Winter S, Klein K et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: Multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10(4), 579-599 (2009
44. Toyoda Y, Sakurai A, Mitani Y et al Earwax, osmidrosis, and breast cancer: Why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type? FASEB J. 23(6), 2001-2013 (2009
45. Brough R, Papanastasiou AM, Porter AC. Stringent and reproducible tetracycline-regulated transgene expression by site-specific insertion at chromosomal loci with pre-characterised induction characteristics. BMC Mol. Biol. 8, 30 (2007
46. Arlanov R, Porter A, Strand D et al. Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells. Hum. Mutat. 33(4), 750-762 (2012
47. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55(5), 929-937 (1999
48. González JR, Armengol L, Solé X et al. SNPassoc: An R package to perform whole genome association studies. Bioinformatics 23(5), 644-645 (2007
49. Hothorn T, Hornik K, van de Wiel MA, Zeileis A. A lego system for conditional inference. Am. Stat. 60(3), 257-263 (2006
50. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4(7), 1073-1081 (2009
51. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248-249 (2010
52. Ishikawa T, Toyoda Y, Yoshiura K, Niikawa N. Pharmacogenetics of human ABC transporter ABCC11: New insights into apocrine gland growth and metabolite secretion. Front. Gene 3, 306 (2012
53. Lang T, Justenhoven C, Winter S et al. The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans. Breast Cancer Res. Treat. 129(3), 993-999 (2011
54. Beesley J, Johnatty SE, Chen X et al. No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. Breast Cancer Res. Treat. 126(1), 235-239 (2011
55. Mochizuki K, Kagawa T, Numari A et al. Two N-linked glycans are required to maintain the transport activity of the bile salt export pump (ABCB11) in MDCK II cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292(3), G818-G828 (2007
56. Guo Y, Köck K, Ritter CA et al. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: Relation to long-term survival. Clin. Cancer Res. 15(5), 1762-1769 (2009
57. Payton JE, Grieselhuber NR, Chang LW et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J. Clin. Invest. 119(6), 1714-1726 (2009
58. Buzzeo MP, Yang J, Casella G, Reddy V. Hematopoietic stem cell mobilization with G-CSF induces innate inflammation yet suppresses adaptive immune gene expression as revealed by microarray analysis. Exp. Hematol. 35(9), 1456-1465 (2007
59. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18(1), 136-147 (2000
60. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000
61. Mukherjee S, Hurt CN, Bridgewater J et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, Phase 2 trial. Lancet Oncol. 14(4), 317-326 (2013
62. Yoshimura K, Uehara K, Tojima Y et al. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: SDtudy protocol for a randomized controlled trial. Trials 14, 17 (2013
63. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 28(12), 1457-1463 (2000
64. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34(8), 1274-1281 (1998
65. Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study. Ann. Oncol. 22(2), 355-361 (2011
66. Martinez-Balibrea E, Abad A, Martínez- Cardús A et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br. J. Cancer 103(4), 581-589 (2010